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Running Title  
Inositol for ovulation Induction in PCOS 
 
Abstract 
Background: Polycystic ovary syndrome is a common cause of anovulation and infertility, 
and a risk factor for development of metabolic syndrome and endometrial cancer.  
Objectives:  Systematic review and meta-analysis of randomised controlled trials that 
evaluated the effects of inositol as an ovulation-induction agent.  
Search Strategy: We searched MEDLINE, EMBASE, Cochrane and ISI conference 
proceedings, Register and Meta-register for RCTs and WHO trials’ search portal. 
Selection Criteria: We included studies that compared inositol with placebo or other 
ovulation induction agents. 
Data Collection and Analysis: Quality of studies was assessed for risk of bias. Results were 
pooled using random effects meta-analysis and findings were reported as relative risk or 
standardized mean differences.  
 
Main Results: We included 10 randomised trials. Total women on inositol were 362 (myo-
inositol = 257; di-chiro-inositol = 105), placebo were 179 and metformin were 60. Inositol 
was associated with significantly improved ovulation rate (RR 2.3; 95% CI 1.1, 4.7; I2 = 
75%) and increased frequency of menstrual cycles (RR 6.8; 95% CI 2.8, 16.6; I2 = 0%) 
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compared with placebo. One study reported on clinical pregnancy rate with inositol compared 
with placebo (RR 3.3; 95% CI 0.4, 27.1), and one study compared with metformin (RR 1.5; 
95% CI 0.7, 3.1). No studies evaluated live birth and miscarriage rates. 
 
Conclusions: Inositol appears to regulate menstrual cycles, improve ovulation and induce 
metabolic changes in PCOS, however evidence is lacking for pregnancy, miscarriage or live 
birth. Further well-designed multicenter trial to address this issue to provide robust evidence 
of benefit is warranted.  
 
Funding: None 
 
Key words: PCOS, inositol, ovulation induction, meta analysis. 
 
A tweetable abstract: Inositols improve menstrual cycles, ovulation and metabolic changes in PCOS 
 
Introduction  
 
Absence of ovulation is a key problem in women who are diagnosed with polycystic ovary syndrome 
(PCOS), a condition also characterised by hyperandrogenaemia, hyperinsulinaemia and a typical 
sonographic ovarian morphology.1 It affects up to 1 in 6 women, and is a major contributor to 
infertility.2,3 In the long term, it increases the risk of endometrial hyperplasia and endometrial 
cancer.4 Furthermore, it predisposes women to type 2 diabetes mellitus, and associated 
cardiovascular complications.5,6  The obesity epidemic may be a contributory factor to the increasing 
numbers diagnosed with PCOS.7 
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Regarding fertility, lifestyle interventions targeting weight loss remain the primary therapy 
in PCOS, since reduction in weight of as little as 5% can restore regular menstruation and 
improve response to ovulation inducing agents, but it is known to be associated with low 
adherence and sustainability.
8,9
 Pharmacological ovulation induction options include 
clomiphene citrate or metformin or a combination of both.
10,11
 If clomiphene citrate is given, 
ultrasound monitoring is necessary in secondary care, to guide dose adjustment and monitor 
complications including multiple pregnancy, which is reported to be about 10%.
12
 Moreover, 
it is not advisable to continue the treatment longer than 6 months (may be considered up to 12 
months) for women who are taking clomiphene citrate.
13,14
 
 
Inositols (myo-inositol and di-chiro inositol) are nutritional supplements, available over-the-counter. 
In PCOS women, a defect in tissue availability or altered metabolism of inositol and/or 
inositolphosphoglycans mediators (second messenger pathway in insulin signaling) has been 
suggested to contribute to insulin resistance.15 Studies have also demonstrated a physiological role 
of inositol and its metabolites in human reproduction and supplementation has proposed to improve 
endocrine and reproductive outcome in these women, including ovulation, in women with PCOS, at 
low cost and potentially with fewer side effects.16  
 
The primary studies on inositol are too small,17 and existing reviews are narrative, without 
quantifiable estimates of effect on ovulation and live births.18–20 We aimed to undertake a systematic 
review to assess the effects of inositol on ovulation induction and reproductive outcomes, as well as 
on hormonal and glycaemic profile, when compared to placebo and/or metformin or clomiphene, in 
women with PCOS.  
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Methods 
Literature search  
We searched MEDLINE (1950 to Aug 2016), EMBASE (1980 to Aug 2016), the Cochrane Library, ISI 
conference proceedings for randomised controlled trials on the effects of myo-inositol on ovulation, 
clinical pregnancy rate, miscarriage rate, live birth rate and hormonal and glycaemic profile in 
women with PCOS. We also searched for ongoing and archived RCTs using the International 
Standard Randomised Controlled Trial Number (ISRCTN) Register and Meta-register for RCTs 
(http://www.controlled-trials.com), and WHO trials’ search portal (ICTRP, 
apps.who.int/trialsearch/Trial). We combined the Medical Subject Headings (MeSH) and text words 
for PCOS (PCOS; Polycystic ovary syndrome; polycystic ovar*; PCO)’and ‘Inositol’ (Inositol; myo-
inositol; DCI; di-chiro-inositol). The reference lists of all known primary and review articles were 
examined for relevant citations not captured by the electronic searches. There were no language 
restrictions.  
 
Study selection 
Studies were selected in a two-step process by two independent researchers (JP, DP). In the first 
step, we reviewed the abstracts of identified studies for potential eligibility. The full texts of studies 
that were considered to be relevant were retrieved in the second stage for detailed evaluation. Any 
disagreements about inclusion were resolved by consensus or arbitration by a third reviewer (ST). 
We included studies if the target population was women with polycystic ovary syndrome undergoing 
treatment for ovulation induction. The intervention was inositol (myo- or di chiro isomers) compared 
with placebo, clomiphene and/or metformin. We also included studies that compared the effects of 
the two isomeric forms of inositol. The primary outcomes were rates of ovulation induction, and 
clinical pregnancy and live births. We considered menstrual regularisation as a surrogate marker of 
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ovulation. Secondary outcomes were changes in hormonal (total androgens, total testosterone, free 
testosterone, Dehydroepiandrosterone, and Sex hormone-binding globulin levels) and glycaemic 
(fasting insulin, fasting glucose, glucose/insulin ratio, homeostatic model assessment (HOMA - a 
method used to quantify insulin resistance) profiles. In cases of duplicate publication, the most 
recent or complete versions were selected. We excluded observational studies.  
 
Assessment of study quality and data extraction 
Two independent reviewers completed data extraction (DP and MA) and quality assessment (JP and 
DP). The qualities of included studies were assessed using the Cochrane risk of bias tool. We 
obtained information on adequacy of randomisation, allocation concealment, blinding, intention-to-
treat analysis, incomplete outcome data, selective outcome reporting, follow-up rates and other 
potential sources of bias. Data were extracted in 2x2 tables for dichotomous outcomes, and as 1 x 2 
tables for continuous outcomes.  
 
Analysis 
We estimated the relative risk (RR) for dichotomous outcomes, and standardized mean difference 
(SMD) with 95% CI for each study. The estimates were pooled using random effects meta-analysis. 
We considered P < 0.05 to be statistically significant. The results from individual studies were pooled 
using either a fixed effect 21 or random effects model as appropriate 22. We evaluated the statistical 
Heterogeneity of the exposure effects graphically using forest plots 23 and statistically using the I2 
statistic 24. All statistical analyses were performed using RevMan 5.2.7 software (Cochrane 
Collaboration, Oxford, UK). A funnel plot was produced to assess publication bias for the primary 
outcome measure. 
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Results 
From 107 potential citations, we included 10 studies (601 women) in the review. Fig 1 provides the 
details of study identification and selection. The list of included and excluded studies is provided in 
Table S3 and search strategy is provided as Appendix S1. Inositol (myo-inositol or di-chiro-inositol) 
was compared with placebo in seven trials,25, 26, 27, 28, 29, 30, 31 myo-inositiol was compared with di-
chiro-inositol and with placebo in a three arm trial,32 myo-inositiol was compared with di-chiro-
inositol in one trial,33 and one trial compared myo-inositol with metformin.34 We found no 
randomised controlled trials which compared myo-inositol with clomiphene. Total women included 
on inositol were 362 (myo-inositol = 257; di-chiro-inositol = 105), on placebo were 179 and on 
metformin were 60. 
 
Characteristics and quality of the included studies  
One  study involved obese women with PCOS 31, and others did not pre-specify or included women 
of any BMI.  All the studies used pre-defined criteria for PCOS, and the population was relatively 
homogeneous by meeting the Rotterdam diagnostic criteria for PCOS.35 Eight trials studied myo-
inositol in doses ranging from 1.2 to 4 g; two evaluated di-chiro inositol with doses from 600 mg to 
1.2 g. Seven trials evaluated the effects of inositol on reproductive, hormonal, and glycaemic 
outcomes.  Pregnancy rates with myo-inositol was reported in two trials,29,34 five studies reported 
ovulation induction.26,29–31,34 Three trial reported on the improved frequency of menstrual 
cycles,28,32,33 and six trials reported the effects of on hormonal profile such as serum total androgens, 
total testosterone, free testosterone, dehydroepiandrosterone, and sex hormone-binding globulin 
levels, and on glycaemic outcomes such as serum fasting insulin, fasting glucose, glucose/insulin 
ratio, homeostatic model assessment to quantify insulin resistance, glucose area under the curve 
and insulin area under the curve.28,25–27,30,31 The details of the study characteristics are provided in 
Table S1.  
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The risk of bias in selection for randomisation was low in half the trials (5/10), and 20% (2/10) had 
low risk of allocation concealment. The risk of bias in performance was low in 70% studies (7/10), 
which blinded participants and/or health care providers and the outcome assessors. There was no 
attrition bias in any of the studies. The quality of the included studies is provided in Fig S1 and Table 
S2.  
 
Effects of inositol on reproductive outcomes 
Ovulation induction  
In anovulatory women with PCOS, treatment with inositol significantly increased the ovulation rate 
(RR 2.3; 95% CI 1.1, 4.7; I2 = 75%) compared with placebo (Fig 2a). One small study (120 women) that 
compared the effects of myo-inositol and metformin found no differences between the groups (RR 
1.5; 95% CI 0.7, 3.1).34  
In women diagnosed with PCOS and known to oligo or amenorrhoea, inositol increases frequency of 
menstrual cycles 6 fold (RR 6.8; 95% CI 2.8, 16.6; I2 = 0%) compared with placebo. There was no 
difference in cycle regularisation between myo-inositol and di-chiro- inositol (RR 1.0; 95% CI 0.8, 1.3) 
(Fig 2b). Sensitivity analysis by including studies on menstrual regularisation as a surrogate for 
ovulation induction showed a three-fold increase in the effect with inositol than placebo (RR 3.2; 
95% CI 1.4, 7.1) (Figure S2).  
 
Pregnancy outcomes 
When compared to placebo, there were no differences in the rates of clinical pregnancy with 
myo - inositol (RR 3.30; 95% CI 0.40, 27.13) in one study involving 92 women, but the study 
was underpowered for this outcome.
29
 There was no difference in clinical pregnancy rate 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
between myo-inositol and metformin in another small study of 120 women (RR 1.64; 95% CI 
0.85, 3.16).
34
 No studies evaluated live birth and miscarriage rates as an outcome. (Figure 2c) 
 
Effects of inositol on hormonal profile  
Treatment with inositol in anovulatory women with PCOS showed a significant decrease in levels of 
total androgen (Standardised Mean Difference (SMD)-1.6; 95% CI -2.5, -0.6; p =0.001), total 
testosterone (SMD -3.3; 95% CI -5.1, -1.5; p =0.0004), free testosterone (SMD -4.4; 95% CI -9.0, 0.2; p 
= 0.06) and serum DHEA (SMD -3.2; 95% CI -5.7, -0.6; p =0.02) compared to placebo. The levels of 
SHBG were significantly increased (SMD 1.3; 95% CI 0.9, 1.7; p <0.00001) (Figure 3).  
 
Effects of inositol on glycaemic parameters  
Treatment with inositol in anovulatory women with PCOS significantly decreased levels of serum 
fasting insulin (SMD -2.1, 95% CI -3.2, -0.9; p =0.0003), fasting glucose (SMD -1.0 95% CI -1.7, -0.2; p 
=0.01), HOMA (SMD -1.8; 95% CI -2.6, -1.0; p<0.00001) and insulin area under the curve (AUC) (SMD 
-1.6; 95% CI -2.8, -0.4; p=0.01). The decrease in glucose area under the curve was not significant 
(SMD -2.7; 95% CI -5.5, 0.1; p=0.06). Glucose/Insulin ratio was significantly higher with inositol 
compared with the placebo group (SMD 2.9; 95% CI 2.2, 3.6; p<0.00001) (Figure 4). 
 
The shape of the funnel plot for each indicator of the ovulation and metabolic factors did not reveal 
any asymmetry (Figure S3). 
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Discussion   
Main Findings 
In women with PCOS, inositol supplementation appears to increase the rates of ovulation and 
frequency of menstrual cycles. Two trials evaluated CPR with inositol, and both showed no 
differences to placebo or metformin respectively, although studies were underpowered and no 
studies reported live birth or miscarriage rates. There was a consistent improvement in glycaemic 
parameters such as fasting glucose, insulin levels and insulin resistance with inositol compared with 
placebo. The levels of total androgens, serum testosterone and DHEA were lowered significantly, 
and levels of SHBG were improved with inositol. There were no differences in the performance of di-
chiro or myo-inositol for any of the above outcomes. 
 
Strengths and Limitations 
To our knowledge, this is the first systematic review to provide quantitative estimates on the effects 
of inositol polymers on ovulation and explore them in pregnancy rates in women with PCOS. We 
adopted stringent inclusion criteria and included only RCTs to remove potential bias. We did not 
have any language restrictions. All studies used pre-defined Rotterdam diagnostic criteria for 
PCOS,35 however they were heterogeneous by BMI status and ethnicity. We studied the effects of 
myo-inositol on both clinical and laboratory parameters. In addition to inositol vs. placebo, we 
compared the performances of the inositol polymers against each other, and against metformin.  
 
The meta-analysis included small numbers of studies with relatively small sample sizes. This 
contributed to the imprecision in estimates. Studies varied in the type of outcomes reported, 
and used inconsistent and proxy measures for insulin resistance to assess them. There was 
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variation in the dose and type of inositol and the duration of follow-up in these studies, 
leading to heterogeneity in the findings. Very few studies reported on clinical pregnancy 
rates, none were powdered for this outcome and none reported on the clinically relevant 
outcome of live birth. We analysed outcomes of ovulation rate and menstrual regularisation 
separately, and also performed sensitivity analysis by combining these together considering 
menstrual regularisation as a proxy for ovulation. Both these outcomes individually and in 
combination showed significant improvement with inositol.  
 
 
Interpretation 
The Cochrane review36 included only two studies 31, 37 on the effects of insulin sensitising agents on 
ovulation induction suggested a potential benefit with di-chiro inositol which was not significant. 
Other systematic reviews on inositol in PCOS did not provide summary estimates of benefit.17,18 In 
comparison, we have included additional studies, 25, 26, 27, 28, 29, 30, 32, 33, 34 with improved precision in 
estimates for ovulation induction. Only two studies reported on clinical pregancny pregnancy rate 
comparing with placebo and metformin respectively.29,34 None of the studies compared inositol with 
clomifene and none reported on miscarriage or live birth rates. Randomised trials on myo-inositol in 
pregnancy have also shown preliminary beneficial effects in reducing the risk of gestational 
diabetes38 which is likely to be mediated through an improvement in insulin sensitisation.  
 
Insulin resistance and hyperinsulinemia is an intrinsic feature of both obese and non-obese PCOS 
women. It is observed in up to 95% of obese women and 75% of lean PCOS women,39 and is 
considered to play a key role in the pathogenesis of anovulation, increased ovarian testosterone 
production and development of various features of metabolic syndrome.40 Moreover, women with 
PCOS have an increased risk and prevalence of obesity, which further exacerbates the intrinsic PCOS 
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related insulin resistance and worsens clinical features.39,41,42 Insulin sentisers sensitisers and lifestyle 
have been used to treat PCOS, however they fail to normalise insulin resistance and further 
interventions are needed.36,39,43  
 
In anovulatory women diagnosed with PCOS, a defect in tissue availability, or altered metabolism of 
inositol and/or inositolphosphoglycans mediators (involved in the second messenger pathway of 
insulin signaling) have been suggested to contribute to insulin resistance.15 Inositol, a vitamin B 
complex nutritional supplement is available as an over-the-counter product. Epimerization of the six 
hydroxyl groups of inositol leads to the formation of up to nine stereoisomers. Of these myo-inositol 
and di-chiro-inositol, may have a potential role in improving endocrine and reproductive outcome in 
women with PCOS, because of their involvement, as second messengers of insulin resulting in insulin 
sensitisation.16,31 
 
PCOS has clinical implications throughout a woman’s lifespan and it is also relevant to family 
members with an increased risk for metabolic conditions reported in first-degree relatives. From a 
public health point of view, it has a huge economic burden on the health care system due to both 
reproductive issues and long term chronic morbidity effecting later part of the life.4,44 The costs of 
evaluating for PCOS and its associated morbidities, and treating the long-term morbidities, exceed 
$4 billion annually in 2004 dollars in the United States alone.4 Furthermore, these women also have 
obstetrical complications including high risk of gestational diabetes.45,46 
 
Until now, insulin-sensitizing compounds, such as metformin, pioglitazone and troglitazone, have 
been considered to induce ovulation and improve features of metabolic syndrome in women with 
PCOS.36 Of these, thiazolidinedione, category C  drug, is associated with significant adverse effects 
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such as myocardial infarction47 weight gain, and adverse effects in animal studies in pregnancy. 
Therefore they are unlikely to have a major clinical role in treating women with PCOS. While 
metformin has a role in reducing insulin resistance, it does not normalise insulin resistance in PCOS 
and has limited efficacy in infertility and its use is limited by mild gastrointestinal side effects 
possibly reducing compliance. 
 
Our systematic review has shown a clear benefit with inositol in improving ovulation rate and 
on the hormonal and glycaemic profile in women with PCOS. Whether this translates into 
clinical benefit with improved pregnancy and increased live birth rate and into reduced 
development of metabolic complications including gestational diabetes, type II diabetes or 
metabolic disease is yet to be shown. If found to be effective at improving primary clinical 
outcomes, inositol supplementation, alongside life style advice could become a first line 
treatment to improve fertility in women with PCOS. By regularising menstrual cycles, it also 
has the potential to also reduce the burden of endometrial hyperplasia and malignancy in 
these women. With no significant side effects, and easy accessibility, it is likely to result in 
high compliance. Unlike clomiphene citrate, the supplement could be provided in primary 
care settings and does not require expensive specialist review and monitoring.  
 
There is a clear need for a large randomised trial to compare the effects of inositol alongside 
lifestyle advice compared with placebo and life style advice as a first line of treatment for 
reproductive outcomes across ovulation induction, pregnancy rates and and live birth rates in 
women with PCOS. The possibility of addition of clomifene and/or metformin in both arms 
after a set period of trial with the above needs be further evaluated. Likewise, longer term 
studies on the effect of inositol on metabolic outcomes and pregnancy outcomes is also 
warranted.  
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Conclusion  
Inositol appears to significantly improve the ovulation rate, metabolic and hormonal profile 
in women with PCOS compared to placebo. There is a need to assess its effect on pregnancy 
and live birth rates and on longer term metabolic health outcomes. This review shows 
promising but preliminary favorable results with myo-inositol in women with polycystic 
ovary syndrome and further well-designed and well-conducted multicenter trial to address 
this issue to provide robust evidence of benefit is warranted before its widespread use can be 
recommended. 
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Fig 2a. Forest plot of comparison; Inositol vs Placebo, outcome: Ovulation. 
 
 
Fig 2b. Forest plot of comparison; Myo-Inositol vs Placebo; Myo-Inositol vs Di-Chorio-Inositol, 
outcome: Menstrual cycle regularisation 
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Fig 2c. Forest plot of comparison; Myo-Inositol vs Placebo; Myo-Inositol vs Metformin, outcome: 
Clinical Pregnancy Rate. 
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Figure 3: Forest plot of comparison; Inositol vs Placebo, outcome: Hormonal factors. 
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Figure 4: Forest plot of comparison; Inositol vs Placebo, outcome: Glycaemic factors. 
 
 
 
 
 
